Lansoprazole Zydus

Lansoprazole, the active ingredient in Lansoprazole Zydus, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid secretion and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease and erosive oesophagitis.

GNH USA supplies Lansoprazole Zydus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal disorders.

- Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief by reducing gastric acid exposure to the esophagus. - Peptic ulcer disease: promotes ulcer healing by maintaining a higher gastric pH. - Erosive oesophagitis: facilitates mucosal recovery through sustained acid suppression. - Helicobacter pylori eradication (in combination therapy): enhances eradication rates when used with antibiotics.

Lansoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: watery stools. - Nausea: feeling of queasiness. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis. - Acute interstitial nephritis: kidney inflammation. - Severe allergic reaction: rash, swelling, difficulty breathing.

Before prescribing Lansoprazole, consider the following precautions.

- Assess renal function: adjust use in patients with severe renal impairment. - Evaluate hepatic status: use with caution in moderate to severe liver disease. - Monitor long‑term therapy: prolonged use may increase risk of bone fractures. - Review concomitant medications: potential for reduced efficacy of drugs requiring acidic pH. - Pregnancy and lactation: safety not established; prescribe only if benefit outweighs risk. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Lansoprazole can interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption due to increased gastric pH. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations. - Warfarin: potential increase in INR, monitor coagulation.

Moderate Interactions (Monitor Closely): - Clopidogrel: reduced antiplatelet effect. - Digoxin: increased serum levels. - Methotrexate: higher exposure, especially at high doses. - Oral contraceptives: possible decreased efficacy.